Prognostic impact of estimated remnant-like particle cholesterol in patients with differing glycometabolic status: an observational cohort study from China

[1]  ESC / EAS Guidelines for the Treatment of Dyslipidemias: Lipid Modification to Reduce Cardiovascular Risk , 2020, Digital Doctor.

[2]  Bilian Yu,et al.  Comparison of calculated remnant lipoprotein cholesterol levels with levels directly measured by nuclear magnetic resonance , 2020, Lipids in Health and Disease.

[3]  M. Sabatine,et al.  2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. , 2019, European heart journal.

[4]  J. Obata,et al.  Remnant Lipoproteins Are Residual Risk Factor for Future Cardiovascular Events in Patients With Stable Coronary Artery Disease and On-Statin Low-Density Lipoprotein Cholesterol Levels <70 mg/dL. , 2019, Circulation Journal.

[5]  S. Nicholls,et al.  Remnant cholesterol and coronary atherosclerotic plaque burden assessed by computed tomography coronary angiography. , 2019, Atherosclerosis.

[6]  Yu-jie Zhou,et al.  Remnant lipoproteins play an important role of in-stent restenosis in type 2 diabetes undergoing percutaneous coronary intervention: a single-centre observational cohort study , 2019, Cardiovascular Diabetology.

[7]  C. Packard.  Determinants of Achieved LDL Cholesterol and “Non-HDL” Cholesterol in the Management of Dyslipidemias , 2018, Current Cardiology Reports.

[8]  B. Cariou,et al.  Beyond LDL: What Role for PCSK9 in Triglyceride-Rich Lipoprotein Metabolism? , 2018, Trends in Endocrinology & Metabolism.

[9]  C. Voermans,et al.  Remnant Cholesterol Elicits Arterial Wall Inflammation and a Multilevel Cellular Immune Response in Humans , 2017, Arteriosclerosis, thrombosis, and vascular biology.

[10]  A. Keech,et al.  Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease , 2017, The New England journal of medicine.

[11]  J. Obata,et al.  Remnant lipoproteinemia predicts cardiovascular events in patients with type 2 diabetes and chronic kidney disease. , 2017, Journal of Cardiology.

[12]  M. Shao,et al.  Non-HDL Cholesterol and Triglycerides: Implications for Coronary Atheroma Progression and Clinical Events , 2016, Arteriosclerosis, thrombosis, and vascular biology.

[13]  R. D'Agostino,et al.  Remnant Lipoprotein Cholesterol and Incident Coronary Heart Disease: The Jackson Heart and Framingham Offspring Cohort Studies , 2016, Journal of the American Heart Association.

[14]  Hiroshi Ito,et al.  Postprandial hyperlipidemia as a potential residual risk factor. , 2016, Journal of cardiology.

[15]  B. Nordestgaard,et al.  Increased Remnant Cholesterol Explains Part of Residual Risk of All-Cause Mortality in 5414 Patients with Ischemic Heart Disease. , 2016, Clinical chemistry.

[16]  B. Nordestgaard.  Triglyceride-Rich Lipoproteins and Atherosclerotic Cardiovascular Disease: New Insights From Epidemiology, Genetics, and Biology. , 2016, Circulation research.

[17]  Jeroen J. Bax,et al.  2015 ESC Guidelines for the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-segment Elevation. , 2015, Revista espanola de cardiologia.

[18]  G. Maurer,et al.  Premature myocardial infarction is strongly associated with increased levels of remnant cholesterol. , 2015, Journal of clinical lipidology.

[19]  J. Mckenney,et al.  National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2. , 2015, Journal of clinical lipidology.

[20]  S. Kihara,et al.  Impact of Remnant Lipoprotein on Coronary Plaque Components. , 2015, Journal of atherosclerosis and thrombosis.

[21]  Improve-It Investigators.  Ezetimibe added to statin therapy after acute coronary syndromes , 2015 .

[22]  D. Demicco,et al.  Fasting triglycerides predict recurrent ischemic events in patients with acute coronary syndrome treated with statins. , 2015, Journal of the American College of Cardiology.

[23]  J. Mckenney,et al.  National lipid association recommendations for patient-centered management of dyslipidemia: part 1--full report. , 2015, Journal of clinical lipidology.

[24]  D. Rader,et al.  Triglyceride-rich lipoproteins and coronary artery disease risk: new insights from human genetics. , 2015, Arteriosclerosis, thrombosis, and vascular biology.

[25]  Takamitsu Nakamura,et al.  High remnant lipoprotein predicts recurrent cardiovascular events on statin treatment after acute coronary syndrome. , 2014, Circulation journal : official journal of the Japanese Circulation Society.

[26]  He Zhang,et al.  Loss-of-function mutations in APOC3, triglycerides, and coronary disease. , 2014, The New England journal of medicine.

[27]  S. Grundy.  An International Atherosclerosis Society Position Paper: global recommendations for the management of dyslipidemia. , 2013, Journal of clinical lipidology.

[28]  B. Nordestgaard,et al.  Elevated Remnant Cholesterol Causes Both Low-Grade Inflammation and Ischemic Heart Disease, Whereas Elevated Low-Density Lipoprotein Cholesterol Causes Ischemic Heart Disease Without Inflammation , 2013, Circulation.

[29]  B. Nordestgaard,et al.  Genetically elevated non-fasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction. , 2013, European heart journal.

[30]  C. Ballantyne,et al.  Icosapent ethyl for the treatment of hypertriglyceridemia , 2013, Expert opinion on pharmacotherapy.

[31]  Richard G. Lee,et al.  Antisense Oligonucleotide Inhibition of Apolipoprotein C-III Reduces Plasma Triglycerides in Rodents, Nonhuman Primates, and Humans , 2013, Circulation research.

[32]  B. Nordestgaard,et al.  Remnant cholesterol as a causal risk factor for ischemic heart disease. , 2013, Journal of the American College of Cardiology.

[33]  D. Waters,et al.  Determinants of Residual Risk in Secondary Prevention Patients Treated With High- Versus Low-Dose Statin Therapy: The Treating to New Targets (TNT) Study , 2012, Circulation.

[34]  Jeroen J. Bax,et al.  ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation , 2012 .

[35]  P. O S I T I O N S T A T E M E N T.  Diagnosis and Classification of Diabetes Mellitus , 2011, Diabetes Care.

[36]  Jeroen J. Bax,et al.  2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). , 2011, European heart journal.

[37]  G. Riccardi,et al.  Ezetimibe beneficially influences fasting and postprandial triglyceride-rich lipoproteins in type 2 diabetes. , 2011, Atherosclerosis.

[38]  J. Borén,et al.  Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management , 2011, European heart journal.

[39]  V. Basevi.  Diagnosis and Classification of Diabetes Mellitus , 2011, Diabetes Care.

[40]  M. Gnant,et al.  Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials , 2010 .

[41]  R. Collins,et al.  Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials , 2010, The Lancet.

[42]  F. Van de Werf,et al.  Underestimated and under-recognized: the late consequences of acute coronary syndrome (GRACE UK-Belgian Study). , 2010, European heart journal.

[43]  G. Rossi.  Diagnosis and Classification of Diabetes Mellitus , 2011, Diabetes Care.

[44]  E. Schaefer,et al.  Relative atherogenicity and predictive value of non-high-density lipoprotein cholesterol for coronary heart disease. , 2008, The American journal of cardiology.

[45]  Christopher P Cannon,et al.  Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. , 2008, Journal of the American College of Cardiology.

[46]  Y. Matsuzawa,et al.  Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis , 2007, The Lancet.

[47]  G. Assmann,et al.  Gap between guidelines and practice: attainment of treatment targets in patients with primary hypercholesterolemia starting statin therapy. Results of the 4E-Registry (Efficacy Calculation and Measurement of Cardiovascular and Cerebrovascular Events including Physicians' Experience and Evaluation) , 2006, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.

[48]  Tom Greene,et al.  Using Standardized Serum Creatinine Values in the Modification of Diet in Renal Disease Study Equation for Estimating Glomerular Filtration Rate , 2006, Annals of Internal Medicine.

[49]  Takamitsu Nakamura,et al.  Remnant lipoproteinemia is a risk factor for endothelial vasomotor dysfunction and coronary artery disease in metabolic syndrome. , 2005, Atherosclerosis.

[50]  K. Kugiyama,et al.  Prognostic value of remnant-like lipoprotein particle levels in patients with coronary artery disease and type II diabetes mellitus. , 2004, Journal of the American College of Cardiology.

[51]  R. Krauss.  Lipids and lipoproteins in patients with type 2 diabetes. , 2004, Diabetes care.

[52]  B. Schreiber,et al.  β-Migrating Very Low Density Lipoprotein (βVLDL) Activates Smooth Muscle Cell Mitogen-activated Protein (MAP) Kinase via G Protein-coupled Receptor-mediated Transactivation of the Epidermal Growth Factor (EGF) Receptor , 2001, The Journal of Biological Chemistry.

[53]  K. Kugiyama,et al.  Remnant lipoproteins induce proatherothrombogenic molecules in endothelial cells through a redox-sensitive mechanism. , 2000, Circulation.

[54]  H Yasue,et al.  Remnant lipoprotein levels in fasting serum predict coronary events in patients with coronary artery disease. , 1999, Circulation.

[55]  K. Kugiyama,et al.  Association of remnant lipoprotein levels with impairment of endothelium-dependent vasomotor function in human coronary arteries. , 1998, Circulation.

[56]  M. Nakashima,et al.  Aggregation of Human Blood Platelets by Remnant Like Lipoprotein Particles of Plasma Chylomicrons and Very Low Density Lipoproteins , 1997, Thrombosis and Haemostasis.

[57]  [Chinese guideline for percutaneous coronary intervention(2016)]. , 2016, Zhonghua xin xue guan bing za zhi.

[58]  S. Grundy,et al.  An International Atherosclerosis Society Position Paper: global recommendations for the management of dyslipidemia--full report. , 2014, Journal of clinical lipidology.

[59]  Alex P. Reiner,et al.  Loss-of-Function Mutations in APOC 3 , Triglycerides , and Coronary Disease , 2014 .

[60]  M. Taskinen,et al.  [ESC/EAS Guidelines for the management of dyslipidaemias]. , 2011, Revista espanola de cardiologia.

[61]  J. Obata,et al.  High serum levels of remnant lipoproteins predict ischemic stroke in patients with metabolic syndrome and mild carotid atherosclerosis. , 2009, Atherosclerosis.

[62]  Diagnosis and Classification of Diabetes Mellitus , 2003 .

[63]  B. Schreiber,et al.  beta-Migrating very low density lipoprotein (beta VLDL) activates smooth muscle cell mitogen-activated protein (MAP) kinase via G protein-coupled receptor-mediated transactivation of the epidermal growth factor (EGF) receptor: effect of MAP kinase activation on beta VLDL plus EGF-induced cell prolif , 2001, Journal of Biological Chemistry.